(Q42984186)

English

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

scientific article published on July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial (English)

1 reference

Europe PubMed Central

12 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Angelo Andriulli

13

1 reference

Europe PubMed Central

12 November 2017

author name string

G Saracco

1

1 reference

Europe PubMed Central

12 November 2017

E Borghesio

2

1 reference

Europe PubMed Central

12 November 2017

P Mesina

3

1 reference

Europe PubMed Central

12 November 2017

A Solinas

4

1 reference

Europe PubMed Central

12 November 2017

C Spezia

5

1 reference

Europe PubMed Central

12 November 2017

F Macor

6

1 reference

Europe PubMed Central

12 November 2017

V Gallo

7

1 reference

Europe PubMed Central

12 November 2017

L Chiandussi

8

1 reference

Europe PubMed Central

12 November 2017

C Donada

9

1 reference

Europe PubMed Central

12 November 2017

V Donadon

10

1 reference

Europe PubMed Central

12 November 2017

F Spirito

11

1 reference

Europe PubMed Central

12 November 2017

A Mangia

12

1 reference

Europe PubMed Central

12 November 2017

G Verme

14

1 reference

Europe PubMed Central

12 November 2017

M Rizzetto

15

1 reference

Europe PubMed Central

12 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 1997

1 reference

Europe PubMed Central

12 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

12 November 2017

27

1 reference

Europe PubMed Central

12 November 2017

56-62

1 reference

Europe PubMed Central

12 November 2017

1

1 reference

Europe PubMed Central

12 November 2017

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose interferon treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Benelux Multicentre Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of anti-IFN-alpha antibody titres during interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980280-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(97)80280-2

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42984186&oldid=2116596574"